Results 201 to 210 of about 1,143,268 (362)

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Centering the voices of young people who use opioids and youth harm reduction practitioners: insights from an international Youth RISE cohort. [PDF]

Harm Reduct J
Juristia A, Azvian V, Arredondo C, Calzada R, Rivera AC, Wambui S, Etepesit WO, Goodyear T.   +7 more
europepmc   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Intranasal Mucosal Atomiser Devices: A Novel Harm Reduction Intervention. [PDF]

Drug Alcohol Rev
Green H, Naren T, Chapman B, Lloyd-Jones M, Crawford S, Membrey D.   +5 more
europepmc   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Social Media Engagement, Youth E-Cigarette Use, and the Moderating Potential of Harm Perceptions. [PDF]

Tob Use Insights
Jackman E, Burrow-Sánchez JJ, Cohen A.
europepmc   +1 more source

Harm reduction in Europe: mapping coverage and civil society advocacy.

, 2011
The european Harm Reduction network, or euroHRn, was formed in 2009 by ten civil society organisations with a shared interest in advocating for and sharing knowledge on harm reduction within europe.
Stoicescu, Claudia, Cook, Catherine
core  

Harm reduction [PDF]

Tobacco Control, 2003
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Exploring Patterns of Self-Harm in Autistic Adults Using the Card Sort Task for Self-Harm. [PDF]

Autism
Pelton M, Newell V, French B, Wadman R, Townsend E, Cassidy S.   +5 more
europepmc   +1 more source